MXPA02004255A - Formas polimorficas de hidrocloruro de sertralina. - Google Patents
Formas polimorficas de hidrocloruro de sertralina.Info
- Publication number
- MXPA02004255A MXPA02004255A MXPA02004255A MXPA02004255A MXPA02004255A MX PA02004255 A MXPA02004255 A MX PA02004255A MX PA02004255 A MXPA02004255 A MX PA02004255A MX PA02004255 A MXPA02004255 A MX PA02004255A MX PA02004255 A MXPA02004255 A MX PA02004255A
- Authority
- MX
- Mexico
- Prior art keywords
- sertraline
- hydrochloride
- sertraline hydrochloride
- polymorphic form
- solution
- Prior art date
Links
- 229960003660 sertraline hydrochloride Drugs 0.000 title claims abstract description 107
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 title claims abstract description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000012453 solvate Substances 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000010521 absorption reaction Methods 0.000 claims abstract description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 45
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 37
- 229960002073 sertraline Drugs 0.000 claims description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 27
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 27
- 150000001412 amines Chemical class 0.000 claims description 26
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 26
- 239000013078 crystal Substances 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 238000001069 Raman spectroscopy Methods 0.000 claims description 15
- 238000000862 absorption spectrum Methods 0.000 claims description 10
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 18
- 238000001237 Raman spectrum Methods 0.000 description 11
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- -1 compound sertraline hydrochloride Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002083 X-ray spectrum Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99810981 | 1999-10-29 | ||
| PCT/EP2000/010416 WO2001032601A1 (en) | 1999-10-29 | 2000-10-23 | Polymorphic forms of sertraline hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02004255A true MXPA02004255A (es) | 2002-10-17 |
Family
ID=8243113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02004255A MXPA02004255A (es) | 1999-10-29 | 2000-10-23 | Formas polimorficas de hidrocloruro de sertralina. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6872853B1 (https=) |
| EP (1) | EP1224160B1 (https=) |
| JP (1) | JP2003513062A (https=) |
| CN (1) | CN1384816A (https=) |
| AR (1) | AR026293A1 (https=) |
| AT (1) | ATE409684T1 (https=) |
| AU (1) | AU1386301A (https=) |
| CA (1) | CA2387135A1 (https=) |
| DE (1) | DE60040406D1 (https=) |
| HU (1) | HUP0203559A3 (https=) |
| IL (2) | IL149050A0 (https=) |
| MX (1) | MXPA02004255A (https=) |
| MY (1) | MY141509A (https=) |
| TR (1) | TR200201146T2 (https=) |
| TW (1) | TWI260315B (https=) |
| WO (1) | WO2001032601A1 (https=) |
| ZA (1) | ZA200203254B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| HK1040979A1 (zh) * | 1998-11-27 | 2002-06-28 | Teva Pharmaceutical Industries Ltd. | 盐酸舍曲林多晶型物 |
| EP1632474A1 (en) * | 1998-11-27 | 2006-03-08 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| US7442838B2 (en) * | 1999-10-29 | 2008-10-28 | Ciba Specialty Chemicals Corp. | Polymorphic forms of sertraline hydrochloride |
| US20050119351A1 (en) * | 1999-10-29 | 2005-06-02 | Van Der Schaaf Paul A. | Polymorphic forms of sertraline hydrochloride |
| EP1774965A3 (en) * | 1999-12-21 | 2007-10-10 | Teva Pharmaceutical Industries Ltd | Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them |
| ES2281374T3 (es) * | 1999-12-21 | 2007-10-01 | Teva Pharmaceutical Industries Ltd. | Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion. |
| IN192343B (https=) * | 2000-05-26 | 2004-04-10 | Ranbaxy Lab Ltd | |
| CA2448279A1 (en) | 2001-05-31 | 2002-12-05 | Orion Corporation Fermion | Process for preparing sertraline hydrochloride polymorphic form ii |
| AU2003251290A1 (en) * | 2002-04-29 | 2003-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
| MXPA04011375A (es) * | 2002-06-27 | 2005-02-14 | Interdigital Tech Corp | Controlador de red de radio para intercambio de informacion de equipo. |
| WO2005000786A1 (en) | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
| JP4791970B2 (ja) | 2003-11-04 | 2011-10-12 | シプラ・リミテッド | 選択的セロトニン再取込み阻害剤の多形体の製造方法 |
| EP1711493A2 (en) * | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
| EP1893559A2 (en) * | 2005-06-09 | 2008-03-05 | Teva Pharmaceutical Industries Ltd | Process for preparation of sertraline hydrochloride form i |
| US7518019B2 (en) | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
| CA2594198A1 (en) * | 2007-07-20 | 2009-01-20 | Apotex Pharmachem Inc. | A novel process for the preparation of sertraline hydrochloride form ii |
| US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
| US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
| WO2012138710A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Personal cleansing compositions with increased deposition of polyacrylate microcapsules |
| WO2012138696A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
| WO2012138690A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
| CN105061217A (zh) * | 2015-06-30 | 2015-11-18 | 徐静 | 枸橼酸舍曲林的2种晶型及其制备方法 |
| US12486478B2 (en) | 2020-10-16 | 2025-12-02 | The Procter & Gamble Company | Consumer products comprising delivery particles with high core:wall ratios |
| US12227720B2 (en) | 2020-10-16 | 2025-02-18 | The Procter & Gamble Company | Consumer product compositions with at least two encapsulate populations |
| CN116323893A (zh) | 2020-10-16 | 2023-06-23 | 宝洁公司 | 包含包封物群体的消费产品组合物 |
| CN112552188B (zh) * | 2020-12-17 | 2023-07-28 | 山西仟源医药集团股份有限公司 | 盐酸舍曲林晶型i的制备方法 |
| CN113588626B (zh) * | 2021-08-24 | 2024-05-24 | 上海师范大学 | 一种苯丙氨酸对映体的拉曼光谱检测方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US5082970A (en) | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
| GB9114947D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5734083A (en) | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
| HU222341B1 (hu) | 1996-12-18 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier |
| EP0928784B1 (en) | 1997-12-11 | 2002-06-12 | TORCAN CHEMICAL Ltd | Sertraline polymorph having improved water solubility |
| ES2217748T3 (es) | 1998-03-18 | 2004-11-01 | Ciba Specialty Chemicals Holding Inc. | Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas. |
| JP2000026378A (ja) | 1998-07-03 | 2000-01-25 | Sumika Fine Chemicals Co Ltd | 塩酸セルトラリンの製法 |
| HK1040979A1 (zh) | 1998-11-27 | 2002-06-28 | Teva Pharmaceutical Industries Ltd. | 盐酸舍曲林多晶型物 |
| US6500987B1 (en) | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
| US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
| ES2281374T3 (es) | 1999-12-21 | 2007-10-01 | Teva Pharmaceutical Industries Ltd. | Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion. |
-
2000
- 2000-10-07 TW TW089120975A patent/TWI260315B/zh not_active IP Right Cessation
- 2000-10-20 MY MYPI20004969A patent/MY141509A/en unknown
- 2000-10-23 WO PCT/EP2000/010416 patent/WO2001032601A1/en not_active Ceased
- 2000-10-23 CN CN00815052A patent/CN1384816A/zh active Pending
- 2000-10-23 JP JP2001534755A patent/JP2003513062A/ja not_active Withdrawn
- 2000-10-23 AT AT00975896T patent/ATE409684T1/de not_active IP Right Cessation
- 2000-10-23 CA CA002387135A patent/CA2387135A1/en not_active Abandoned
- 2000-10-23 HU HU0203559A patent/HUP0203559A3/hu unknown
- 2000-10-23 IL IL14905000A patent/IL149050A0/xx active IP Right Grant
- 2000-10-23 TR TR2002/01146T patent/TR200201146T2/xx unknown
- 2000-10-23 AU AU13863/01A patent/AU1386301A/en not_active Abandoned
- 2000-10-23 US US10/111,947 patent/US6872853B1/en not_active Expired - Fee Related
- 2000-10-23 EP EP00975896A patent/EP1224160B1/en not_active Expired - Lifetime
- 2000-10-23 DE DE60040406T patent/DE60040406D1/de not_active Expired - Fee Related
- 2000-10-23 MX MXPA02004255A patent/MXPA02004255A/es active IP Right Grant
- 2000-10-27 AR ARP000105711A patent/AR026293A1/es not_active Application Discontinuation
-
2002
- 2002-04-09 IL IL149050A patent/IL149050A/en not_active IP Right Cessation
- 2002-04-24 ZA ZA200203254A patent/ZA200203254B/xx unknown
-
2003
- 2003-12-15 US US10/736,195 patent/US6939992B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6872853B1 (en) | 2005-03-29 |
| AU1386301A (en) | 2001-05-14 |
| US20040132828A1 (en) | 2004-07-08 |
| MY141509A (en) | 2010-05-14 |
| EP1224160B1 (en) | 2008-10-01 |
| CN1384816A (zh) | 2002-12-11 |
| HUP0203559A3 (en) | 2008-01-28 |
| IL149050A (en) | 2007-03-08 |
| IL149050A0 (en) | 2002-11-10 |
| AR026293A1 (es) | 2003-02-05 |
| US6939992B2 (en) | 2005-09-06 |
| CA2387135A1 (en) | 2001-05-10 |
| TWI260315B (en) | 2006-08-21 |
| JP2003513062A (ja) | 2003-04-08 |
| ZA200203254B (en) | 2003-07-22 |
| HUP0203559A2 (hu) | 2003-03-28 |
| WO2001032601A1 (en) | 2001-05-10 |
| EP1224160A1 (en) | 2002-07-24 |
| DE60040406D1 (de) | 2008-11-13 |
| ATE409684T1 (de) | 2008-10-15 |
| TR200201146T2 (tr) | 2004-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02004255A (es) | Formas polimorficas de hidrocloruro de sertralina. | |
| EP1956015B2 (en) | Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same | |
| JP2005503386A5 (https=) | ||
| KR20180030964A (ko) | 이브루티닙과 카복실산의 공결정체 | |
| JP2002519422A (ja) | パロキセチンメタンスルホネート | |
| JP2019523273A (ja) | ベリノスタットの多形形態、およびその調製のためのプロセス | |
| EP2085377A1 (en) | Novel salts of O-desmethyl-venlafaxine | |
| US6706710B2 (en) | Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide | |
| WO2007128561A1 (en) | Crystalline forms of letrozole and processes for making them | |
| AU2001272872A1 (en) | Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide | |
| EP2155698A1 (en) | Novel thermodynamically stable polymorphic form-l of letrozole | |
| JP2004512282A (ja) | １−［６−クロロ−５−（トリフルオロメチル）−２−ピリジニル］ピペラジン塩酸塩の結晶形態 | |
| WO2019072864A1 (en) | PROCESS FOR THE PREPARATION OF AGOMÉLATINE IN CRYSTALLINE FORM | |
| JP5156381B2 (ja) | Ｎ−メチル−Ｎ−（３−｛３−［２−チエニルカルボニル］−ピラゾール−［１，５−α］−ピリミジン−７−イル｝フェニル）アセトアミドの水和物ならびにそれに関連するプロセスおよび方法 | |
| JP4275241B2 (ja) | Ｎ−グリシルチロシンの製造方法及びその結晶形 | |
| JP2008531510A (ja) | ６−ジメチルアミノメチル−１−（３−メトキシフェニル）−１，３−ジヒドロキシ−シクロヘキサン化合物のリン酸塩 | |
| MXPA02008538A (es) | Procedimiento para la preparacion de compuestos de 2-(4-alquil-1-piperacinil)-benzaldehido y -bencilidenilo. | |
| HK1118293B (en) | Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same | |
| PL216883B1 (pl) | Sposób wytwarzania krystalicznej formy a soli addycyjnej kwasu metanosulfonowego i 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-[(4-pirydyn-3-ylo)pirymidyn-2- -yloamino)fenylo]benzamidu | |
| JPWO2002020516A1 (ja) | １，３，４−オキサジアゾール誘導体の新規結晶、その製造方法およびそれを有効成分として含有する薬剤 | |
| SK50092006A3 (sk) | Soli aripiprazolu a spôsob ich prípravy | |
| WO2006010653A1 (en) | New polymorphous form of rosiglitazone maleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |